Dallas, Texas 02/07/2014 (FINANCIALSTRENDS) – The S&P 500 index tracked , $33 billion market capped generic drug maker Actavis plc Ordinary Shares (NYSE:ACT) provided a reiteration of its 2013 estimates and provided significantly stronger estimates for its 2014 operations on the sidelines of its annual investor general body meeting. For the full year operations of 2013, it hopes to bring in earnings which would be in the range of $9.26 –$9.39 per share.
From its 2014 full year operations, Actavis plc Ordinary Shares (NYSE:ACT) estimates revenue generation to range around the $10 billion. This would translate into a earnings per share of $12.6 to$13.1 per share which would be a minimum 20 percent increase in its EPS on a year on year compare.
Actavis plc Ordinary Shares (NYSE:ACT) also shared insights into its reworked global operations and go to market strategy. It hopes to expand its drug pipeline by taking this accommodative approach in order to assimilate the operations of its bought out firm Chilcott (it was bought in 2013) and adopt a more strategic business structure which is aligned to operate more efficiently.
The new org structure stipulates that all of, “Actavis’ existing global generics, specialty brands, branded generics, legacy brands, over-the-counter (:OTC) and third-party commercial operations and business development activities ” have been rolled into one big single unit reporting into a single individual. In conjunction, the “research and development (R&D) organizations of the generic, brand, inhalation and biosimilars divisions” have also been consolidated under a single unit. This business model, the firm believes will provide it the required economies of scale across its divisions.
As part of the re-org plans, the drug maker hopes to transform itself into a speciality pharma firm which focuses its efforts on developing drugs designed to cater to needs of women’s health including treatments for “urology, gastroenterology and dermatology” related ailments.